CancerSnoop Research ExplainedAt a glanceFrontline blinatumomab B-ALL: Frontline…

FDA Approves Tucatinib Combo for Ongoing HER2-Positive Breas
CancerSnoop News
Tucatinib approval: The FDA has approved a new combination of medicines to help adults with certain advanced breast cancers keep their disease under control after initial treatment.
What happened
On October 7, 2026, the Food and Drug Administration (FDA) approved tucatinib (brand name Tukysa) to be used alongside trastuzumab and pertuzumab for maintenance treatment of adults with HER2-positive breast cancer that cannot be removed by surgery or has spread to other parts of the body. This approval follows initial treatment cycles and aims to prevent cancer from growing again.
The approval is based on a study involving 654 patients who had advanced HER2-positive breast cancer and had already received 4 to 8 cycles of trastuzumab, pertuzumab, and a taxane chemotherapy. Patients receiving tucatinib had a longer period without cancer progression — nearly 25 months compared to about 16 months for those who did not receive tucatinib.
Who this concerns
This new treatment option is important for adults living with HER2-positive breast cancer that is locally advanced or has spread and who have completed initial treatment cycles with trastuzumab, pertuzumab, and chemotherapy.
What the evidence shows
The approval comes from results of the HER2CLIMB-05 clinical trial, which was a rigorous, randomized, and controlled study. It showed that adding tucatinib to trastuzumab and pertuzumab extended the time patients lived without their cancer worsening.
However, at the time of analysis, data on overall survival (how long patients lived) had not yet matured.
What remains unclear
While tucatinib helps delay cancer progression, it can cause serious side effects, including liver damage and diarrhea. There is also a risk of harm to an unborn baby, so embryo-fetal toxicity is a concern.
Healthcare providers need to watch for these issues carefully. Additionally, it remains unclear how tucatinib affects overall survival, as that data is not yet available.
Bottom line
For adults with advanced HER2-positive breast cancer, the FDA’s approval of tucatinib combined with trastuzumab and pertuzumab offers an important new option to keep the cancer from growing after initial treatment. Patients and families should discuss the benefits and risks of this treatment with their healthcare team.
